A A

References

  1. Simpson PT, Gale T, Fulford LG, et al. The diagnosis and management of pre-invasive breast disease. Pathology of atypical lobular hyperplasia and lobular carcinoma in situ. Breast Cancer Res. 2003;5(5):258-262.
  2. Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumours of the breast, fourth edition. Who Classification of Tumours. IARC Who Classification of Tumours. 2012.
  3. Philpotts L, Shaheen N, Jain K, et al. Uncommon High-Risk Lesions of the Breast Diagnosed at Stereotactic Core-Needle Biopsy: Clinical Importance. Radiology. 2000;216(3):831-837.
  4. Berg WA, Mrose HE and Loffe OB. Atypical Lobular Hyperplasia or Lobular Carcinoma in Situ at Core-Needle Breast Biopsy. Radiology. 2001;218(2):503-509.
  5. Page DL, Travis EK, Dupont WD, et al. Lobular neoplasia of the breast: higher risk for subsequent invasive cancer predicted by more extensive disease. Human Pathology. 1991;22(12):1232-1239.
  6. King TA, Pilewskie M, Muhsen S, et al. Lobular Carcinoma in Situ: A 29-year longitudinal experience evaluating clinicopathologic features and breast cancer risk. Journal of Clinical Oncology. 2015;33(33):3945-3952.
  7. Fisher ER, Land SR, Fisher B, et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ. Cancer. 2004;100(2):238-44.
  8. Lakhani SR, Audretsch W, Cleton-Jensen AM, et al. The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? Eur J Cancer. 2006;42(14):2205-11.
  9. Page DL, Schuyler PA, Dupont WD, et al. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet. 2003;361(9352):125-9.
  10. Buckley ES, Webster F, Hiller J, et al. A systematic review of surgical biopsy for LCIS found at core needle biopsy – Do we have the answer yet? European Journal Cancer Surgery. 2014;40(2):168-175.
  11. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. 1998;90(18):1371-1388.
  12. Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. The Lancet Oncology. 2015;16(1):67-75.
  13. Cuzick J, Sestak I, Forbes J, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. The Lancet Oncology. 2014;383(9922):1041-1048.
  14. Goss P, Ingle J, Ales-Martinez J, et al. Exemestane for breast cancer prevention in postmenopausal women. NEJM. 2011;364(25):2381-2391.
  15. Drife J. Oral Contraception and the Risk of Thromboembolism. Drug Safety. 2012;25(13):893-902.
  16. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. 2005;97(22):1652-1662.
  17. Nelson HD, Smith ME, Griffin JC and Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158(8):604-14.
  18. Cuzick J, Sestak I, Bonanni B, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. The Lancet. 2013;381(9880):1827-1834.
  19. Cheung AM, Tile L, Cardew S, et al. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial. The Lancet Oncology. 2012;13(3):275-284.